Difference between revisions of "Vandetanib (Caprelsa)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(updated links)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: from the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=269177 NCI Drug Dictionary]: "An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis." Also a tyrosine kinase inhibitor of RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.<ref name="insert">[http://www1.astrazeneca-us.com/pi/vandetanib.pdf Vandetanib (Caprelsa) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/vandetanib.pdf Vandetanib (Caprelsa) package insert (locally hosted backup)]</ref><ref>[http://www.caprelsa.com Caprelsa manufacturer's website]</ref>
+
Class/mechanism: from the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=269177 NCI Drug Dictionary]: "An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis." Also a tyrosine kinase inhibitor of RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.<ref name="insert">[https://www.caprelsa.com/files/caprelsa-pi.pdf Vandetanib (Caprelsa) package insert]</ref><ref>[[:File:Vandetanib.pdf | Vandetanib (Caprelsa) package insert (locally hosted backup)]]</ref><ref>[http://www.caprelsa.com Caprelsa manufacturer's website]</ref>
 
<br>Route: PO
 
<br>Route: PO
 
<br>Extravasation: n/a
 
<br>Extravasation: n/a
Line 14: Line 14:
  
 
==Patient drug information==
 
==Patient drug information==
−
*[http://www1.astrazeneca-us.com/pi/vandetanib.pdf#page=6 Vandetanib (Caprelsa) package insert PDF pages 6-8]<ref>[http://www1.astrazeneca-us.com/pi/vandetanib.pdf#page=6 Vandetanib (Caprelsa) package insert PDF pages 6-8]</ref>
+
*[https://www.caprelsa.com/files/caprelsa-pi.pdf Vandetanib (Caprelsa) package insert]<ref>[https://www.caprelsa.com/files/caprelsa-pi.pdf Vandetanib (Caprelsa) package insert]</ref>
 +
*[https://chemocare.com/chemotherapy/drug-info/vandetanib.aspx Vandetanib (Caprelsa) patient drug information (Chemocare)]<ref>[https://chemocare.com/chemotherapy/drug-info/vandetanib.aspx Vandetanib (Caprelsa) patient drug information (Chemocare)]</ref>
 
*[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/vandetanib-patient-drug-information Vandetanib (Caprelsa) patient drug information (UpToDate)]</ref>
  

Revision as of 00:05, 1 January 2022

General information

Class/mechanism: from the NCI Drug Dictionary: "An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis." Also a tyrosine kinase inhibitor of RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 4/6/2011: Initial approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. (Based on ZETA)

History of changes in EMA indication

  • 2/16/2012: Initial marketing authorization as Caprelsa.

Also known as

  • Code names: AZD6474, ZD6474
  • Brand names: Caprelsa, Lucivand, Zactima

References

  1. ↑ 1.0 1.1 Vandetanib (Caprelsa) package insert
  2. ↑ Vandetanib (Caprelsa) package insert (locally hosted backup)
  3. ↑ Caprelsa manufacturer's website
  4. ↑ Caprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
  5. ↑ Vandetanib (Caprelsa) package insert
  6. ↑ Vandetanib (Caprelsa) patient drug information (Chemocare)
  7. ↑ Vandetanib (Caprelsa) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Vandetanib_(Caprelsa)&oldid=54096"